MedPage Today on MSN17h
Rapid, Substantial Psoriasis Improvement With Oral IL-23 InhibitorTwo-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...
MedPage Today on MSN18h
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...
Verywell Health on MSN10d
Understanding Scalp Psoriasis and How to Treat ItScalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...
Verywell Health on MSN11d
How to Tell If You May Have Scalp Psoriasis vs. DandruffScalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback